Morgan Stanley Smith Barney files Form 144 for 2,500 shares

Morgan Stanley Smith Barney LLC reported the sale of 2,500 restricted common shares under a registered plan, with the transaction dated 02/20/2026 and the Form 144 filed on 02/23/2026.

Rhea-AI Filing Summary

Morgan Stanley Smith Barney LLC reported the sale of 2,500 restricted common shares under a registered plan, with the transaction dated 02/20/2026 and the Form 144 filed on 02/23/2026. The filing lists an aggregate amount of $105,087.50 and identifies the exchange as NASDAQ.

Insights

Securities Compliance Counsel

Rule 144 sale notice for vested restricted shares, routine compliance disclosure.

The excerpt shows a sale of 2,500 common shares described as "restricted stock vesting under a registered plan" with a transaction date of 02/20/2026 and an aggregate figure of $105,087.50.

Such filings are administrative notifications that permit resale under Rule 144 conditions; cash‑flow treatment and buyer identity are not provided in the excerpt. Subsequent filings may disclose settlement details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 for VERA show?

The Form 144 reports the sale of 2,500 restricted common shares dated 02/20/2026. The filing lists an aggregate amount of $105,087.50 and was filed on 02/23/2026.

Who is the selling party on the Form 144 for VERA?

The filing identifies Morgan Stanley Smith Barney LLC Executive Financial Services as the reporting broker/agent for the transaction. The excerpt labels the transaction as related to the issuer under a registered plan.

What kind of shares were sold according to the VERA filing?

The shares are described as restricted stock vesting under a registered plan. The transaction date is 02/20/2026 and the sale quantity is 2,500 common shares.

Does the Form 144 state which exchange VERA trades on?

Yes. The excerpt lists the exchange as NASDAQ. The filing also contains the transaction and filing dates of 02/20/2026 and 02/23/2026, respectively.

Is the cash‑flow recipient specified in the VERA Form 144?

The excerpt does not specify who receives the sale proceeds. The Form 144 shows an aggregate figure of $105,087.50, but it does not state the recipient or use of proceeds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 04:39 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002006910
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERA THERAPEUTICS, INC.
SEC File Number	001-40407
Address of Issuer	8000 Marina Boulevard Suite 120 Brisbane CALIFORNIA 94005
Phone	650-770-0077
Name of Person for Whose Account the Securities are To Be Sold	ROBERT BRENNER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2500	105087.50	63928066	02/23/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/20/2026	Restricted stock vesting under a registered plan	Issuer			2500	02/20/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Robert Brenner
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)